REMARKS

This document is filed in reply to the Office Action dated March 14, 2005 ("Office Action"). Applicants also file herewith an Information Disclosure Statement.

At the Examiner's request, Applicants have replaced Figures 1-7, 13, and 14 with amended versions that include SEQ ID NOs. The specification is amended to correct an informality. Applicants also amend claim 1 to delete parts (b)-(d) and add new claims 20-31. Claim 2 is amended to promote clarity.

Support for the limitation "wherein the protein binds to a hematopoietin factor" recited in new claim 24 appears at page 8, line 11 of the specification. Support for new claims 20-31 can be found in original claim 1, 3, 5, 7, and 11 and the specification. Examples of the support are listed in Table 1 below. No new matter has been introduced.

Table 1. Support for New Claims

New Claims	Support in
Claim 20	part (b) in original claim 1
Claim 24	part (c) in original claim 1
Claims 21 and 25	original claim 3
Claims 22 and 26	original claim 5
Claims 23 and 27	original claim 7
Claims 28 and 30	original claim 11
Claims 29 and 31	original claim 12

Upon entry of the proposed amendments, claims 1-31 will be pending. Claims 9-19 have been withdrawn from further consideration as drawn to non-elected inventions. Applicants intend to request rejoinder of method claims 11, 12, and 28-31 once the present composition claims are deemed allowable. Claims 1-8 and 20-27 are now under examination. Reconsideration of this application is requested in view of the following remarks.

Objections to the Specification

The Examiner objected to the specification for not complying with the sequence rules. See the Office Action, page 2, lines 8 and 9.

According to the Examiner, the sequences presented in Figures 1-7, 13, and 14 are not referred to by SEQ ID NOs in the "Description of Drawing" section of the specification. Applicants would like to point out that this section was already amended to include SEQ ID NOs that refer to the sequences. See the "Response To Notice To Comply With Requirements For Patent Applications Containing Nucleotide And/Or Amino Acid Sequences" filed on December 30, 2002. The Examiner also requested that SEQ ID NOs be recited in the figures. Applicants have amended the figures accordingly.

In view of the above remarks and amendments, Applicants submit that the objections should be withdrawn.

Rejection under 35 U.S.C. § 101

The Examiner rejected claims 1-8 for lack of utility on various grounds. See page 3, lines 1 and 2 of the Office Action. Applicants traverse each of the grounds below, discussing amended claim 1 first. This claim is drawn to an isolated nucleic acid containing a sequence that encodes a protein comprising the sequence of SEQ ID NO: 2, 4, or 17.

I

The Examiner asserted that "Applicant has not disclosed any specific and substantial utility ... for the claimed invention." See the Office Action, page 3, lines 3 and 4.

Applicants disagree. In fact, the specification discloses that the proteins of SEQ ID NOs: 2, 4, and 17 (NR10.1, NR10.2, and NR10.3, respectively) are hemopoietin receptor proteins. They bind to a hematopoietin factor. See, e.g., the specification, page 3, line 4; and page 8, line 8. Accordingly, they "can be applied for diagnosis and treatment of diseases related to immunity and hematopoiesis." See the specification, page 56, lines 27 and 28. Also, the specification discloses that a soluble extracellular domain of each protein can be used as an inhibitor "to suppress the cellular immunity or inhibit the proliferation of hematopoietic cells *in vivo* ... to suppresses the immune function or inflammation ... [or] to suppress the onset of autoimmune diseases arising from autoimmunity, or tissue rejection by the immune system of the living body, the primary problem in transplantation. Furthermore, the inhibitors may be effectively used to treat such diseases caused by the abnormally upregulated

immune response. Thus, it is possible to use the inhibitors to treat a variety of allergies ..." See the specification, page 57, last paragraph. Treatment of any of the above-mentioned disorders is without question a real-world, i.e., substantial, use. Likewise, each is a "specific" utility, in contrast with a "general" utility that would be applicable to the "broad class of the invention" (i.e., all proteins). The Revised Interim Utility Guidelines Training Materials at page 29 provide some hypothetical examples of utilities for proteins that do not qualify as "specific" utilities because they apply to "virtually every member of a very general class of materials, such as proteins ..." These examples include utility as a source of amino acids or as protein supplements for animal food. In contrast to such utilities that apply to all proteins, the presently asserted utilities clearly cannot be dismissed as "nonspecific."

The above asserted utilities are also credible. The invention of this application is based, at least in part, on the discovery of nucleic acids encoding proteins NR10.1, NR10.2, and NR10.3. Each of the proteins includes motifs that are conserved in well-known human cytokine receptors, such as gp130, leukemia inhibitory factor receptor, Oncostatin M receptor β subunit, IL-12 receptor β2 subunit, and NR6. See the specification, Fig. 2. Examples of the motifs include a WS motif, a YR motif, a proline-rich motif, and a box1 motif. These motifs are responsible for binding to a ligand or mediating signal transduction. See the specification, page 3, lines 20-27; page 4, lines 22-25; page 7, lines 16-21; and Fig. 2. In view of these teachings, one of ordinary skill in the art would recognize that the nucleic acid of claim 1 encodes a cytokine receptor that plays a role in immunity and hematopoiesis, as well as diseases related to those functions. In this connection, Applicants note that

> [T]the applicant does not have to provide evidence sufficient to establish that an asserted utility is true "beyond a reasonable doubt." *In re Irons,* 340 F.2d 974, 978, 144 USPQ 351, 354 (CCPA 1965). Nor must an applicant provide evidence such that it establishes an asserted utility as a matter of statistical certainty. *Nelson v. Bowler*, 626 F.2d 853, 856-57, 206 USPQ 881, 883-84 (CCPA 1980) ... Instead, evidence will be sufficient if, considered as a whole, it leads a person of ordinary skill in the art to conclude that the asserted utility is more likely than not true.

See MPEP 2107.02(VII). Here, a person of ordinary skill in the art to would conclude, based on the evidence in the specification coupled with what was known in the art, that the asserted utilities are more likely than not true. Therefore, it is submitted that the above asserted utilities are credible.

To further support credibility of the asserted utilities, Applicants submit three articles: Dillon et al., "Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice" Nature Immunology 5(7):752-760, July 2004; Diveu et al., "GPL, a Novel Cytokine Receptor Related to GP130 and Leukemia Inhibitory Factor Receptor" J. Biol. Chem. 278(50):49850-49859, December 12, 2003; and Kernebeck et al. "The signal transducer gp130: solution structure of the carboxy-terminal domain of the cytokine receptor homology region" Protein Science 8(1):5-12, 1999. Copies of these references are included in the Information Disclosure Statement filed herewith.

Dillon et al. says that Interleukin 31 (IL-31) signals through a receptor composed of IL-31 receptor A (IL-31 RA) and oncostatin M receptor. See the Abstract. IL-31 was identified via its binding to IL-31 RA variant 4 (IL-31RAV4), the sequence of which is identical to that of NR10.3 (SEQ ID NO: 17). See Dillon et al. page 753, right column, second paragraph. In other words, IL-31 is a ligand of NR10.3. The sequence of IL-31-RA and its alignment against SEQ ID NO: 17 are shown in Exhibits A and B, both attached hereto. Since NR10.3 and NR10.1 have the same extracellular domain and NR10.2 is a splice variant of NR10.1 that lacks transmembrane and intercellular domains but contains the same extracellular domain as NR10.1 and NR10.2, IL-31 is also a ligand of NR10.1 or NR10.2. Dillon et al. further describes transgenic mice that over-express IL-31, as well as non-transgenic mice to whom purified IL-31 was administered. The mice exhibited a phenotype that mimics inflammatory disease and allergy. See, e.g., page 755, right column, through page 757. The IL-31 was shown to be acting via IL-31-RA (page 757, columns 1-2, carryover paragraph).

Diveu et al. describes another IL-31 receptor A named GPL, the sequence of which (shown in Exhibit C) is substantially identical to NR10. According to Diveu et al., expression of GPL is induced by INFγ in monocytes and dendritic cells, suggesting that IL-31 and GPL are involved in inflammatory diseases. See page 49854, right column, lines 9-25.

Kernebeck et al. describes a family of cytokine receptors and domains conserved among its members, including the above-mentioned WS motif.

These three articles support the assertion that NR10.1, NR10.2, and NR10.3 are receptors of cytokines, e.g., IL-31, and are involved in immune system-related disorders, such as allergies and other inflammatory diseases. Accordingly, the receptors and nucleic acids encoding them can be used in isolating the cognate ligand (IL-31) or in treating inflammatory diseases, such as allergies, exactly as stated in the specification. In sum, they have credible utilities.

II

The Examiner asserted that "Applicant has not disclosed any ... well-established utility for the claimed invention." See the Office Action, page 3, lines 3 and 4.

Applicants first point out that a "well-established utility" by definition need not be "disclosed" by an applicant, as such a disclosure would mean it is an "asserted" rather than "well-established" utility. As set forth in MPEP 2107,

> An invention has a well-established utility if (i) a person of ordinary skill in the art would immediately appreciate why the invention is useful based on the characteristics of the invention (e.g., properties or applications of a product or process), and (ii) the utility is specific, substantial, and credible.

As discussed above, the nucleic acids of claim 1, encode hemopoietin factor receptor proteins. It is well known in the art that hemopoietin factors (also known as cytokines) are "involved in systemic humoral regulation of hemopoietic or immune functions." See, e.g., the specification, at the paragraph bridging pages 1 and 2. In view of this knowledge, "a person of ordinary skill in the art would immediately appreciate why the invention is useful based on the characteristics of the invention (e.g., properties or applications of a product or process)." Also, for the remarks set forth above in Part I, a person of ordinary skill in the art would appreciate that the utilities of the invention are "specific, substantial, and credible." Accordingly, the nucleic acids of claim 1 possess well-established utilities.

Claim 2 is drawn to an isolated nucleic acid containing a sequence encoding NR10.1, NR10.2, or NR10.3, or a fragment thereof. Claim 20 is drawn to an isolated nucleic acid containing a coding region of any one of SEQ ID NOs:1, 3, and 16, the nucleotide sequences corresponding to NR10.1, NR10.2, and NR10.3, respectively. Claim 24 covers an isolated

nucleic acid comprising a nucleotide sequence encoding a protein that comprises the amino acid sequence of any one of SEQ ID NOs:2, 4, and 17, with a single amino acid replacement, deletion, insertion, or addition, where the protein binds to a hematopoietin factor. For the same reasons as discussed above for claim 1, these claims also meet the utility requirement. So do claims 3-8, 21-23, and 25-27, which are drawn to vectors or transformants containing the nucleic acid of claim 1, 2, 20, or 24.

Rejection under 35 U.S.C. § 112, first paragraph (enablement)

The Examiner rejected claims 1-8 for lack of enablement, contending that these claims do not meet the utility requirement so one of skill in the art would not know how to use the claimed invention. See page 4, lines 9-12 of the Office Action. As set forth above, all of the claimed invention do possess utilities. Thus, withdrawal of the enablement rejection is respectfully requested.

Rejection under 35 U.S.C. § 112, first paragraph (written description)

The Examiner rejected claims 1, 3, 5, and 7 for not complying with the written description requirement. More specifically, he stated that "[c]laim 1(c) is drawn to a nucleic acid that encodes a modified protein that is functionally equivalent [to] NR10 ... As there is no data regarding a function for ... NR10, one would not be able to determine if the modified protein retained that function." See the Office Action, page 4, lines 17-21.

Applicants have deleted claim 1(c) and added new claim 24. This new claim recites a specific function of NR10. It is therefore submitted that the rejection should be withdrawn.

CONCLUSION

Applicants submit that claims 1-8 and 20-27 are in condition for allowance, and such action is respectfully requested.

Enclosed is a check for $800 for excess claim fees and a $1020 check for the Petition for Extension of Time fee.

Please apply any other charges to deposit account 06-1050, referencing attorney docket 14875-096001.

Respectfully submitted,

Date: 9-14-2005

Jianming Hao, Ph.D.
Reg. No. 54,694

PTO Customer No. 26161
Fish & Richardson P.C.
225 Franklin Street
Boston, MA 02110-2804
Telephone: (617) 542-5070
Facsimile: (617) 542-8906

21049208.doc

Amendments to the Drawings:

The attached replacement sheets of drawings include changes to Figures 1-7, 13, and 14 and replace the original sheets including Figures 1-7, 13, and 14. Applicants have amended the drawings, which show a number of sequences, to include SEQ ID NOs.

Attachments following the last page of this Amendment:

Replacement Sheets (9 pages)

Annotated Sheets Showing Changes (9 pages)

```
LOCUS       AY499342                2903 bp    mRNA    linear   PRI 10-JUL-2004
DEFINITION  Homo sapiens interleukin 31RA splice variant x4 (IL31RA) mRNA,
            complete cds, alternatively spliced.
ACCESSION   AY499342
VERSION     AY499342.1  GI:46276462
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini;
            Hominidae; Homo.
REFERENCE   1  (bases 1 to 2903)
  AUTHORS   Dillon,S.R., Sprecher,C., Hammond,A., Bilsborough,J.,
            Rosenfeld-Franklin,M., Presnell,S.R., Haugen,H.S., Maurer,M.,
            Harder,B., Johnston,J., Bort,S., Mudri,S., Kuijper,J.L.,
            Bukowski,T., Shea,P., Dong,D.L., Dasovich,M., Grant,F.J.,
            Lockwood,L., Levin,S.D., LeCiel,C., Waggie,K., Day,H., Topouzis,S.,
            Kramer,J., Kuestner,R., Chen,Z., Foster,D., Parrish-Novak,J. and
            Gross,J.A.
  TITLE     Interleukin 31, a cytokine produced by activated T cells, induces
            dermatitis in mice
  JOURNAL   Nat. Immunol. 5 (7), 752-760 (2004)
   PUBMED   15184896
REFERENCE   2  (bases 1 to 2903)
  AUTHORS   Dillon,S.R., Sprecher,C., Hammond,A., Rosenfeld-Franklin,M.,
            Presnell,S.R., Haugen,H., Bilsborough,J., Maurer,M., Harder,B.,
            Johnston,J., Bort,S., Mudri,S., Kuijper,J., Bukowski,T., Shea,P.,
            Dong,D., Dasovich,M., Lockwood,L., Levin,S., LeCeil,C., Waggie,K.,
            Kramer,J., Kuestner,R., Chen,Z., Foster,D., Parrish-Novak,J. and
            Gross,J.A.
  TITLE     Direct Submission
  JOURNAL   Submitted (10-DEC-2003) Bioinformatics, ZymoGenetics, Inc., 1201
            Eastlake Avenue East, Seattle, WA 98102, USA
FEATURES             Location/Qualifiers
     source          1..2903
                     /organism="Homo sapiens"
                     /mol_type="mRNA"
                     /db_xref="taxon:9606"
                     /chromosome="5"
                     /map="5q11"
     gene            1..2903
                     /gene="IL31RA"
     CDS             497..2485
                     /gene="IL31RA"
                     /note="class I cytokine receptor; huzcytor17x4;
                     alternatively spliced"
                     /codon_start=1
```

/product="interleukin 31RA splice variant x4"
/protein_id="AAS86447.1"
/db_xref="GI:46276463"
/translation="MKLSPQPSCVNLGMMWTWALWMLPSLCKFSLAALPAKPENISCV
YYYRKNLTCTWSPGKETSYTQYTVKRTYAFGEKHDNCTTNSSTSENRASCSFFLPRIT
IPDNYTIEVEAENGDGVIKSHMTYWRLENIAKTEPPKIFRVKPVLGIKRMIQIEWIKP
ELAPVSSDLKYTLRFRTVNSTSWMEVNFAKNRKDKNQTYNLTGLQPFTEYVIALRCAV
KESKFWSDWSQEKMGMTEEEAPCGLELWRVLKPAEADGRRPVRLLWKKARGAPVLEKT
LGYNIWYYPESNTNLTETMNTTNQQLELHLGGESFWVSMISYNSLGKSPVATLRIPAI
QEKSFQCIEVMQACVAEDQLVVKWQSSALDVNTWMIEWFPDVDSEPTTLSWESVSQAT
NWTIQQDKLKPFWCYNISVYPMLHDKVGEPYSIQAYAKEGVPSEGPETKVENIGVKTV
TITWKEIPKSERKGIICNYTIFYQAEGGKGFSKTVNSSILQYGLESLKRKTSYIVQVM
ASTSAGGTNGTSINFKTLSFSVFEIILITSLIGGGLLILIIILTVAYGLKKPNKLTHLC
WPTVPNPAESSIATWHGDDFKDKLNLKESDDSVNTEDRILKPCSTPSDKLVIDKLVVN
FGNVLQEIFTDEARTGQENNLGGEKNGTRILSSCPTSI"

ORIGIN

```
        1 tgaaaagaca tgtgtgtgca gtatgaaaat tgagacagga aggcagagtg tcagcttgtt
       61 ccacctcagc tgggaatgtg catcaggcaa ctcaagtttt tcaccacggc atgtgtctgt
      121 gaatgtccgc aaaacattag tttcactctt gtcgccaggt tggagtacaa tggcacgatc
      181 ttggctcact gcaacctctg cctcccgggt tcaagcgatt ctcctgcctc agcctcccga
      241 gtagctggga ttacagttaa caataatgca atccatttcc cagcataagt gggtaagtgc
      301 cactttgact tgggctgggc ttaaaagcac aagaaaagct cgcagacaat cagagtggaa
      361 acactcccac atcttagtgt ggataaatta aagtccagat tgttcttcct gtcctgactt
      421 gtgctgtggg aggtggagtt gcctttgatg caaatccttt gagccagcag aacatctgtg
      481 gaacatcccc tgatacatga agctctctcc ccagccttca tgtgttaacc tggggatgat
      541 gtggacctgg gcactgtgga tgctcccttc actctgcaaa ttcagcctgg cagctctgcc
      601 agctaagcct gagaacattt cctgtgtcta ctactatagg aaaaatttaa cctgcacttg
      661 gagtccagga aaggaaacca gttataccca gtacacagtt aagagaactt acgcttttgg
      721 agaaaaacat gataattgta caaccaatag ttctacaagt gaaaatcgtg cttcgtgctc
      781 ttttttcctt ccaagaataa cgatcccaga taattatacc attgaggtgg aagctgaaaa
      841 tggagatggt gtaattaaat ctcatatgac atactggaga ttagagaaca tagcgaaaac
      901 tgaaccacct aagattttcc gtgtgaaacc agttttgggc atcaaacgaa tgattcaaat
      961 tgaatggata aagcctgagt tggcgcctgt ttcatctgat ttaaaataca cacttcgatt
     1021 caggacagtc aacagtacca gctggatgga agtcaacttc gctaagaacc gtaaggataa
     1081 aaaccaaacg tacaacctca cggggctgca gcctttttaca gaatatgtca tagctctgcg
     1141 atgtgcggtc aaggagtcaa agttctggag tgactggagc caagaaaaaa tgggaatgac
     1201 tgaggaagaa gctccatgtg gcctggaact gtggagagtc ctgaaaccag ctgaggcgga
     1261 tggaagaagg ccagtgcggt tgttatggaa gaaggcaaga ggagccccag tcctagagaa
     1321 aacacttggc tacaacatat ggtactatcc agaaagcaac actaacctca cagaaacaat
     1381 gaacactact aaccagcagc ttgaactgca tctgggaggc gagagctttt gggtgtctat
     1441 gatttcttat aattctcttg ggaagtctcc agtggccacc ctgaggattc cagctattca
     1501 agaaaaatca tttcagtgca ttgaggtcat gcaggcctgc gttgctgagg accagctagt
     1561 ggtgaagtgg caaagctctg ctctagacgt gaacacttgg atgattgaat ggtttccgga
     1621 tgtggactca gagcccacca ccctttcctg ggaatctgtg tctcaggcca cgaactggac
     1681 gatccagcaa gataaattaa aacctttctg gtgctataac atctctgtgt atccaatgtt
     1741 gcatgacaaa gttggcgagc catattccat ccaggcttat gccaaagaag gcgttccatc
     1801 agaaggtcct gagaccaagg tggagaacat tggcgtgaag acggtcacga tcacatggaa
     1861 agagattccc aagagtgaga gaaagggtat catctgcaac tacaccatct tttaccaagc
     1921 tgaaggtgga aaaggattct ccaagacagt caattccagc atcttgcagt acggcctgga
     1981 gtccctgaaa cgaaagacct cttacattgt tcaggtcatg gccagcacca gtgctggggg
     2041 aaccaacggg accagcataa atttcaagac attgtcattc agtgtctttg agattatcct
     2101 cataacttct ctgattggtg gaggccttct tattctcatt atcctgacag tggcatatgg
     2161 tctcaaaaaa cccaacaaat tgactcatct gtgttggccc accgttccca accctgctga
     2221 aagtagtata gccacatggc atggagatga tttcaaggat aagctaaacc tgaaggagtc
     2281 tgatgactct gtgaacacag aagacaggat cttaaaacca tgttccaccc ccagtgacaa
     2341 gttggtgatt gacaagttgg tggtgaactt tgggaatgtt ctgcaagaaa ttttcacaga
     2401 tgaagccaga acgggtcagg aaaacaattt aggaggggaa aagaatggga ctagaattct
     2461 gtcttcctgc ccaacttcaa tataagtgtg gactaaaatg cgagaaaggt gtcctgtggt
     2521 ctatgcaaat tagaaaggac atgcagagtt ttccaactag gaagactgaa tctgtggccc
     2581 caagagaacc atctctgaag actgggtatg tggtcttttc cacacatgga ccacctacgg
     2641 atgcaatctg taatgcatgt gcatgagaag tctgttatta agtagagtgt gaaaacatgg
     2701 ttatggtaat aggaacagct tttaaaatgc ttttgtattt gggcctttca tacaaaaaag
     2761 ccataatacc attttcatgt aatgctatac ttctatacta ttttcatgta atactatact
```

```
     2821 tctatactat tttcatgtaa tactatactt ctatactatt ttcatgtaat actatacttc
     2881 tatattaaag ttttacccac tca
//
```


Aug 8 2005 15:12:56

********** [align] **********

options = -align -matrix=blosum -gapdist=8 -maxdiv=40 -outorder=aligned
-pwmatrix=blosum

CLUSTAL W (1.83) Multiple Sequence Alignments

Sequence type explicitly set to Protein
Sequence format is Pearson
Sequence 1: IL-31RA 662 aa
Sequence 2: seq17 662 aa
Start of Pairwise alignments
Aligning...

== Aligned score is not displayed ==

Guide tree file created:
[/disk/www/html/homology/c_results/20050803111354_9106/query.dnd]
Start of Multiple Alignment
There are 1 groups
Aligning...

== Aligned score is not displayed ==

Alignment Score 4166
CLUSTAL-Alignment file created
[/disk/www/html/homology/c_results/20050803111354_9106/query.aln]

query.aln
CLUSTAL W (1.83) multiple sequence alignment

```
IL-31RAV4       MKLSPQPSCVNLGMMWTWALWMLPSLCKFSLAALPAKPENISCVYYYRKNLTCTWSPGKE
seq17           MKLSPQPSCVNLGMMWTWALWMLPSLCKFSLAALPAKPENISCVYYYRKNLTCTWSPGKE
                ************************************************************

IL-31RAV4       TSYTQYTVKRTYAFGEKHDNCTTNSSTSENRASCSFFLPRITIPDNYTIEVEAENGDGVI
seq17           TSYTQYTVKRTYAFGEKHDNCTTNSSTSENRASCSFFLPRITIPDNYTIEVEAENGDGVI
                ************************************************************

IL-31RAV4       KSHMTYWRLENIAKTEPPKIFRVKPVLGIKRMIQIEWIKPELAPVSSDLKYTLRFRTVNS
seq17           KSHMTYWRLENIAKTEPPKIFRVKPVLGIKRMIQIEWIKPELAPVSSDLKYTLRFRTVNS
                ************************************************************

IL-31RAV4       TSWMEVNFAKNRKDKNQTYNLTGLQPFTEYVIALRCAVKESKFWSDWSQEKMGMTEEEAP
seq17           TSWMEVNFAKNRKDKNQTYNLTGLQPFTEYVIALRCAVKESKFWSDWSQEKMGMTEEEAP
                ************************************************************

IL-31RAV4       CGLELWRVLKPAEADGRRPVRLLWKKARGAPVLEKTLGYNIWYYPESNTNLTETMNTTNQ
seq17           CGLELWRVLKPAEADGRRPVRLLWKKARGAPVLEKTLGYNIWYYPESNTNLTETMNTTNQ
                ************************************************************

IL-31RAV4       QLELHLGGESFWVSMISYNSLGKSPVATLRIPAIQEKSFQCIEVMQACVAEDQLVVKWQS
seq17           QLELHLGGESFWVSMISYNSLGKSPVATLRIPAIQEKSFQCIEVMQACVAEDQLVVKWQS
                ************************************************************

IL-31RAV4       SALDVNTWMIEWFPDVDSEPTTLSWESVSQATNWTIQQDKLKPFWCYNISVYPMLHDKVG
seq17           SALDVNTWMIEWFPDVDSEPTTLSWESVSQATNWTIQQDKLKPFWCYNISVYPMLHDKVG
                ************************************************************
```

```
IL-31RAV4       EPYSIQAYAKEGVPSEGPETKVENIGVKTVTITWKEIPKSERKGIICNYTIFYQAEGGKG
seq17           EPYSIQAYAKEGVPSEGPETKVENIGVKTVTITWKEIPKSERKGIICNYTIFYQAEGGKG
                ************************************************************

IL-31RAV4       FSKTVNSSILQYGLESLKRKTSYIVQVMASTSAGGTNGTSINFKTLSFSVFEIILITSLI
seq17           FSKTVNSSILQYGLESLKRKTSYIVQVMASTSAGGTNGTSINFKTLSFSVFEIILITSLI
                ************************************************************

IL-31RAV4       GGGLLILIILTVAYGLKKPNKLTHLCWPTVPNPAESSIATWHGDDFKDKLNLKESDDSVN
seq17           GGGLLILIILTVAYGLKKPNKLTHLCWPTVPNPAESSIATWHGDDFKDKLNLKESDDSVN
                ************************************************************

IL-31RAV4       TEDRILKPCSTPSDKLVIDKLVVNFGNVLQEIFTDEARTGQENNLGGEKNGTRILSSCPT
seq17           TEDRILKPCSTPSDKLVIDKLVVNFGNVLQEIFTDEARTGQENNLGGEKNGTRILSSCPT
                ************************************************************

IL-31RAV4       SI
seq17           SI
                **


query.dnd
(IL-31RA:0.00000,seq17:0.00000);


************** [tree] **************

options = -tree -outputtree=phylip -kimura -tossgaps
 CLUSTAL W (1.83) Multiple Sequence Alignments



Sequence format is Clustal
Sequence 1: IL-31RA          662 aa
Sequence 2: seq17            662 aa
Phylogenetic tree file created:
[/disk/www/html/homology/c_results/20050803111354_9106/query.ph]


query.ph
(IL-31RA:0.00000,seq17:0.00000);
```

1: NM_139017. Reports Homo sapiens inte...[gi:38455420] Links

```
LOCUS       NM_139017               2315 bp    mRNA    linear   PRI 03-AUG-2005
DEFINITION  Homo sapiens interleukin 31 receptor A (IL31RA), mRNA.
ACCESSION   NM_139017
VERSION     NM_139017.3  GI:38455420
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini;
            Hominidae; Homo.
REFERENCE   1  (bases 1 to 2315)
  AUTHORS   Dreuw,A., Radtke,S., Pflanz,S., Lippok,B.E., Heinrich,P.C. and
            Hermanns,H.M.
  TITLE     Characterization of the signaling capacities of the novel
            gp130-like cytokine receptor
  JOURNAL   J. Biol. Chem. 279 (34), 36112-36120 (2004)
   PUBMED   15194700
  REMARK    GeneRIF: the molecular mechanisms underlying GPL-mediated signal
            transduction
REFERENCE   2  (bases 1 to 2315)
  AUTHORS   Dillon,S.R., Sprecher,C., Hammond,A., Bilsborough,J.,
            Rosenfeld-Franklin,M., Presnell,S.R., Haugen,H.S., Maurer,M.,
            Harder,B., Johnston,J., Bort,S., Mudri,S., Kuijper,J.L.,
            Bukowski,T., Shea,P., Dong,D.L., Dasovich,M., Grant,F.J.,
            Lockwood,L., Levin,S.D., LeCiel,C., Waggie,K., Day,H., Topouzis,S.,
            Kramer,J., Kuestner,R., Chen,Z., Foster,D., Parrish-Novak,J. and
            Gross,J.A.
  TITLE     Interleukin 31, a cytokine produced by activated T cells, induces
            dermatitis in mice
  JOURNAL   Nat. Immunol. 5 (7), 752-760 (2004)
   PUBMED   15184896
REFERENCE   3  (bases 1 to 2315)
  AUTHORS   Diveu,C., Lelievre,E., Perret,D., Lak-Hal,A.H., Froger,J.,
            Guillet,C., Chevalier,S., Rousseau,F., Wesa,A., Preisser,L.,
            Chabbert,M., Gauchat,J.F., Galy,A., Gascan,H. and Morel,A.
  TITLE     GPL, a novel cytokine receptor related to GP130 and leukemia
            inhibitory factor receptor
  JOURNAL   J. Biol. Chem. 278 (50), 49850-49859 (2003)
   PUBMED   14504285
  REMARK    GeneRIF: GPL is a novel cytokine receptor related to GP130 and
            leukemia inhibitory factor receptor
REFERENCE   4  (bases 1 to 2315)
  AUTHORS   Clark,H.F., Gurney,A.L., Abaya,E., Baker,K., Baldwin,D., Brush,J.,
            Chen,J., Chow,B., Chui,C., Crowley,C., Currell,B., Deuel,B.,
            Dowd,P., Eaton,D., Foster,J., Grimaldi,C., Gu,Q., Hass,P.E.,
            Heldens,S., Huang,A., Kim,H.S., Klimowski,L., Jin,Y., Johnson,S.,
            Lee,J., Lewis,L., Liao,D., Mark,M., Robbie,E., Sanchez,C.,
```

```
            Schoenfeld,J., Seshagiri,S., Simmons,L., Singh,J., Smith,V.,
            Stinson,J., Vagts,A., Vandlen,R., Watanabe,C., Wieand,D., Woods,K.,
            Xie,M.H., Yansura,D., Yi,S., Yu,G., Yuan,J., Zhang,M., Zhang,Z.,
            Goddard,A., Wood,W.I., Godowski,P. and Gray,A.
  TITLE     The secreted protein discovery initiative (SPDI), a large-scale
            effort to identify novel human secreted and transmembrane proteins:
            a bioinformatics assessment
  JOURNAL   Genome Res. 13 (10), 2265-2270 (2003)
   PUBMED   12975309
REFERENCE   5  (bases 1 to 2315)
  AUTHORS   Ghilardi,N., Li,J., Hongo,J.A., Yi,S., Gurney,A. and de
            Sauvage,F.J.
  TITLE     A novel type I cytokine receptor is expressed on monocytes, signals
            proliferation, and activates STAT-3 and STAT-5
  JOURNAL   J. Biol. Chem. 277 (19), 16831-16836 (2002)
   PUBMED   11877449
  REMARK    GeneRIF: A novel type I cytokine receptor is expressed on
            monocytes, signals proliferation, and activates STAT-3 and STAT-5.
COMMENT     VALIDATED REFSEQ: This record has undergone preliminary review of
            the sequence, but has not yet been subject to final review. The
            reference sequence was derived from AF106913.1 and AF486620.1.
            On Nov 20, 2003 this sequence version replaced gi:21314784.
FEATURES             Location/Qualifiers
     source          1..2315
                     /organism="Homo sapiens"
                     /mol_type="mRNA"
                     /db_xref="taxon:9606"
                     /chromosome="5"
                     /map="5q11.2"
     gene            1..2315
                     /gene="IL31RA"
                     /note="synonyms: CRL, GPL, CRL3, GLMR, GLM-R, IL-31RA,
                     PRO21384"
                     /db_xref="GeneID:133396"
                     /db_xref="MIM:609510"
     CDS             117..2315
                     /gene="IL31RA"
                     /note="soluble type I cytokine receptor CRL3; GP130 like
                     receptor; class I cytokine receptor;
                     go_component: integral to membrane [goid 0016021]
                     [evidence NAS] [pmid 11877449];
                     go_function: receptor activity [goid 0004872] [evidence
                     IEA];
                     go_function: cytokine binding [goid 0019955] [evidence
                     NAS] [pmid 11877449];
                     go_function: protein kinase binding [goid 0019901]
                     [evidence NAS] [pmid 11877449];
                     go_function: transcription coactivator activity [goid
                     0003713] [evidence NAS] [pmid 11877449];
                     go_function: hematopoietin/interferon-class (D200-domain)
                     cytokine receptor activity [goid 0004896] [evidence TAS]
                     [pmid 11877449];
                     go_process: homeostasis [goid 0042592] [evidence NAS]
                     [pmid 11877449];
                     go_process: MAPKKK cascade [goid 0000165] [evidence NAS]
                     [pmid 11877449];
                     go_process: anti-apoptosis [goid 0006916] [evidence NAS]
                     [pmid 11877449];
                     go_process: JAK-STAT cascade [goid 0007259] [evidence IEP]
                     [pmid 11877449];
                     go_process: defense response [goid 0006952] [evidence NAS]
                     [pmid 11877449];
                     go_process: macrophage differentiation [goid 0030225]
```

```
                     [evidence NAS] [pmid 11877449];
                     go_process: positive regulation of cell proliferation
                     [goid 0008284] [evidence IDA] [pmid 11877449];
                     go_process: negative regulation of macrophage activation
                     [goid 0043031] [evidence NAS] [pmid 11877449];
                     go_process: cytokine and chemokine mediated signaling
                     pathway [goid 0019221] [evidence TAS] [pmid 11877449];
                     go_process: positive regulation of transcription,
                     DNA-dependent [goid 0045893] [evidence NAS] [pmid
                     11877449];
                     go_process: positive regulation of tyrosine
                     phosphorylation of Stat3 protein [goid 0042517] [evidence
                     IEP] [pmid 11877449];
                     go_process: positive regulation of tyrosine
                     phosphorylation of Stat5 protein [goid 0042523] [evidence
                     IEP] [pmid 11877449];
                     go_process: transmembrane receptor protein tyrosine kinase
                     signaling pathway [goid 0007169] [evidence NAS] [pmid
                     11877449]"
                     /codon_start=1
                     /product="gp130-like monocyte receptor"
                     /protein_id="NP_620586.2"
                     /db_xref="GI:21314785"
                     /db_xref="CCDS:CCDS3970.1"
                     /db_xref="GeneID:133396"
                     /db_xref="MIM:609510"
                     /translation="MMWTWALWMLPSLCKFSLAALPAKPENISCVYYYRKNLTCTWSP
                     GKETSYTQYTVKRTYAFGEKHDNCTTNSSTSENRASCSFFLPRITIPDNYTIEVEAEN
                     GDGVIKSHMTYWRLENIAKTEPPKIFRVKPVLGIKRMIQIEWIKPELAPVSSDLKYTL
                     RFRTVNSTSWMEVNFAKNRKDKNQTYNLTGLQPFTEYVIALRCAVKESKFWSDWSQEK
                     MGMTEEEAPCGLELWRVLKPAEADGRRPVRLLWKKARGAPVLEKTLGYNIWYYPESNT
                     NLTETMNTTNQQLELHLGGESFWVSMISYNSLGKSPVATLRIPAIQEKSFQCIEVMQA
                     CVAEDQLVVKWQSSALDVNTWMIEWFPDVDSEPTTLSWESVSQATNWTIQQDKLKPFW
                     CYNISVYPMLHDKVGEPYSIQAYAKEGVPSEGPETKVENIGVKTVTITWKEIPKSERK
                     GIICNYTIFYQAEGGKGFSKTVNSSILQYGLESLKRKTSYIVQVMASTSAGGTNGTSI
                     NFKTLSFSVFEIILITSLIGGGLLILIILTVAYGLKKPNKLTHLCWPTVPNPAESSIA
                     TWHGDDFKDKLNLKESDDSVNTEDRILKPCSTPSDKLVIDKLVVNFGNVLQEIFTDEA
                     RTGQENNLGGEKNGYVTCPFRPDCPLGKSFEELPVSPEIPPRKSQYLRSRMPEGTRPE
                     AKEQLLFSGQSLVPDHLCEEGAPNPYLKNSVTAREFLVSEKLPEHTKGEV"
ORIGIN
        1 tgtgctgtgg gaggtggagt tgcctttgat gcaaatcctt tgagccagca gaacatctgt
       61 ggaacatccc ctgatacatg aagctctctc cccagccttc atgtgttaac ctggggatga
      121 tgtggacctg ggcactgtgg atgctccctt cactctgcaa attcagcctg gcagctctgc
      181 cagctaagcc tgagaacatt tcctgtgtct actactatag gaaaaattta acctgcactt
      241 ggagtccagg aaaggaaacc agttataccc agtacacagt taagagaact tacgcttttg
      301 gagaaaaaca tgataattgt acaaccaata gttctacaag tgaaaatcgt gcttcgtgct
      361 ctttttttcct tccaagaata acgatcccag ataattatac cattgaggtg gaagctgaaa
      421 atggagatgg tgtaattaaa tctcatatga catactggag attagagaac atagcgaaaa
      481 ctgaaccacc taagattttc cgtgtgaaac cagttttggg catcaaacga atgattcaaa
      541 ttgaatggat aaagcctgag ttggcgcctg tttcatctga tttaaaatac acacttcgat
      601 tcaggacagt caacagtacc agctggatgg aagtcaactt cgctaagaac cgtaaggata
      661 aaaaccaaac gtacaacctc acggggctgc agccttttac agaatatgtc atagctctgc
      721 gatgtgcggt caaggagtca aagttctgga gtgactggag ccaagaaaaa atgggaatga
      781 ctgaggaaga agctccatgt ggcctggaac tgtggagagt cctgaaacca gctgaggcgg
      841 atggaagaag gccagtgcgg ttgttatgga agaaggcaag aggagcccca gtcctagaga
      901 aaacacttgg ctacaacata tggtactatc cagaaagcaa cactaacctc acagaaacaa
      961 tgaacactac taaccagcag cttgaactgc atctgggagg cgagagcttt tgggtgtcta
     1021 tgatttctta taattctctt gggaagtctc cagtggccac cctgaggatt ccagctattc
     1081 aagaaaaatc atttcagtgc attgaggtca tgcaggcctg cgttgctgag gaccagctag
     1141 tggtgaagtg gcaaagctct gctctagacg tgaacacttg gatgattgaa tggtttccgg
     1201 atgtggactc agagcccacc acccttttcct gggaatctgt gtctcaggcc acgaactgga
     1261 cgatccagca agataaatta aaacctttct ggtgctataa catctctgtg tatccaatgt
     1321 tgcatgacaa agttggcgag ccatattcca tccaggctta tgccaaagaa ggcgttccat
```

```
     1381 cagaaggtcc tgagaccaag gtggagaaca ttggcgtgaa gacggtcacg atcacatgga
     1441 aagagattcc caagagtgag agaaagggga tcatctgcaa ctacaccatc ttttaccaag
     1501 ctgaaggtgg aaaaggattc tccaagacag tcaattccag catcttgcag tacggcctgg
     1561 agtccctgaa acgaaagacc tcttacattg ttcaggtcat ggccagcacc agtgctgggg
     1621 gaaccaacgg gaccagcata aatttcaaga cattgtcatt cagtgtcttt gagattatcc
     1681 tcataacttc tctgattggt ggaggccttc ttattctcat tatcctgaca gtggcatatg
     1741 gtctcaaaaa acccaacaaa ttgactcatc tgtgttggcc caccgttccc aaccctgctg
     1801 aaagtagtat agccacatgg catggagatg atttcaagga taagctaaac ctgaaggagt
     1861 ctgatgactc tgtgaacaca gaagacagga tcttaaaacc atgttccacc cccagtgaca
     1921 agttggtgat tgacaagttg gtggtgaact ttgggaatgt tctgcaagaa attttcacag
     1981 atgaagccag aacgggtcag gaaaacaatt taggagggga aaagaatggg tatgtgacct
     2041 gccccttcag gcctgattgt cccctgggga aaagttttga ggagctccca gtttcacctg
     2101 agattccgcc cagaaaatcc caatacctac gttcgaggat gccagagggg acccgcccag
     2161 aagccaaaga gcagcttctc ttttctggtc aaagtttagt accagatcat ctgtgtgagg
     2221 aaggagcccc aaatccatat ttgaaaaatt cagtgacagc cagggaattt cttgtgtctg
     2281 aaaaacttcc agagcacacc aagggagaag tctaa
//
```

Figure 1

```
1     ttggtggttcatggtgatgttctatatctgtgtaagtaccaattgttcccaggcacatat
61    ggaagtctgttaataaaaatgatatattttaaaatttgatttagagtgttactagttcta
121   aaaatgtaaaagtacactaggtagtgaagaggaaaatgggaggataacgtgtggtctcca
181   tttcagtttacgattgtctctgtcttgtagatggaagtcaacttcgctaagaaccgtaag
                                        MetGluValAsnPheAlaLysAsnArgLys

241   gataaaaaccaaacgtacaacctcacggggctgcaaccttntacagaatatgtcatagct
      AspLysAsnGlnThrTyrAsnLeuThrGlyLeuGlnProXxxThrGluTyrValIleAla

301   ctgcgatgtgcggtcaaggagtcaaagttctggagtgactggagccaagaaaaaatggga
      LeuArgCysAlaValLysGluSerLysPheTrpSerAspTrpSerGlnGluLysMetGly

361   atgactgaggaagaangcaagctacttcctgcgattcccgtcctgtctgctctggtgtan
      MetThrGluGluGluXxxLysLeuLeuProAlaIlePro (SEQ ID NO:35)

421   ggctgctctgcgctaaacttggtggtgtctgcaccaccg (SEQ ID NO:34)
```

Figure 2



Figure 3

(SEQ ID NO:1)

```
   1 CGCTTATAAATGAATGTGTGCTTAGGAACACCAGACAGCACTCCAGCACTCTGCTTGGGG
  61 GGCATTCGAAACAGCAAAATCACTCATAAAAGGCAAAAAATTGCAAAAAAAATAGTAATA
 121 ACCAGCATGGTACTAAATAGACCATGAAAAGACATGTGTGTGCAGTATGAAAATTGAGAC
 181 AGGAAGGCAGAGTGTCAGCTTGTTCCACCTCAGCTGGGAATGTGCATCAGGCAACTCAAG
 241 TTTTTCACCACGGCATGTGTCTGTGAATGTCCGCAAAACATTTTAACAATAATGCAATCC
 301 ATTTCCCAGCATAAGTGGGTAAGTGCCACTTTGACTTGGGCTGGGCTTAAAAGCACAAGA
 361 AAAGCTCGCAGACAATCAGAGTGGAAACACTCCCACATCTTAGTGTGGATAAATTAAAGT
 421 CCAGATTGTTCTTCCTGTCCTGACTTGTGCTGTGGGAGGTGGAGTTGCCTTTGATGCAAA
 481 TCCTTTGAGCCAGCAGAACATCTGTGGAACATCCCCTGATACATGAAGCTCTCTCCCCAG
```

(SEQ ID NO:2) MetLysLeuSerProGln

```
 541 CCTTCATGTGTTAACCTGGGGATGATGTGGACCTGGGCACTGTGGATGCTCCCCTCACTC
     ProSerCysValAsnLeuGlyMetMetTrpThrTrpAlaLeuTrpMetLeuProSerLeu
 601 TGCAAATTCAGCCTGGCAGCTCTGCCAGCTAAGCCTGAGAACATTTCCTGTGTCTACTAC
     CysLysPheSerLeuAlaAlaLeuProAlaLysProGluAsnIleSerCysValTyrTyr
 661 TATAGGAAAAATTTAACCTGCACTTGGAGTCCAGGAAAGGAAACCAGTTATACCCAGTAC
     TyrArgLysAsnLeuThrCysThrTrpSerProGlyLysGluThrSerTyrThrGlnTyr
 721 ACAGTTAAGAGAACTTACGCTTTCGGAGAAAAACATGATAATTGTACAACCAATAGTTCT
     ThrValLysArgThrTyrAlaPheGlyGluLysHisAspAsnCysThrThrAsnSerSer
 781 ACAAGTGAAAATCGTGCTTCGTGCTCTTTTTTCCTTCCAAGAATAACGATCCCAGATAAT
     ThrSerGluAsnArgAlaSerCysSerPhePheLeuProArgIleThrIleProAspAsn
 841 TATACCATTGAGGTGGAAGCTGAAAATGGAGATGGTGTAATTAAATCTCATATGACATAC
     TyrThrIleGluValGluAlaGluAsnGlyAspGlyValIleLysSerHisMetThrTyr
 901 TGGAGATTAGAGAACATAGCGAAAACTGAACCACCTAAGATTTTCCGTGTGAAACCAGTT
     TrpArgLeuGluAsnIleAlaLysThrGluProProLysIlePheArgValLysProVal
 961 TTGGGCATCAAACGAATGATTCAAATTGAATGGATAAAGCCTGAGTTGGCGCCTGTTTCA
     LeuGlyIleLysArgMetIleGlnIleGluTrpIleLysProGluLeuAlaProValSer
1021 TCTGATTTAAAATACACACTTCGATTCAGGACAGTCAACAGTACCAGCTGGATGGAAGTC
     SerAspLeuLysTyrThrLeuArgPheArgThrValAsnSerThrSerTrpMetGluVal
1081 AACTTCGCTAAGAACCGTAAGGATAAAAACCAAACGTACAACCTCACGGGGCTGCAGCCT
     AsnPheAlaLysAsnArgLysAspLysAsnGlnThrTyrAsnLeuThrGlyLeuGlnPro
1141 TTTACAGAATATGTCATAGCTCTGCGATGTGCGGTCAAGGAGTCAAAGTTCTGGAGTGAC
     PheThrGluTyrValIleAlaLeuArgCysAlaValLysGluSerLysPheTrpSerAsp
```

Figure 4

(SEQ ID NO:1)

1201 TGGAGCCAAGAAAAAATGGGAATGACTGAGGAAGAAGCTCCATGTGGCCTGGAACTGTGG

(SEQ ID NO:2)

TrpSerGlnGluLysMetGlyMetThrGluGluGluAlaProCysGlyLeuGluLeuTrp

1261 AGAGTCCTGAAACCAGCTGAGGCGGATGGAAGAAGGCCAGTGCGGTTGTTATGGAAGAAG

ArgValLeuLysProAlaGluAlaAspGlyArgArgProValArgLeuLeuTrpLysLys

1321 GCAAGAGGAGCCCCAGTCCTAGAGAAAACACTTGGCTACAACATATGGTACTATCCAGAA

AlaArgGlyAlaProValLeuGluLysThrLeuGlyTyrAsnIleTrpTyrTyrProGlu

1381 AGCAACACTAACCTCACAGAAACAATGAACACTACTAACCAGCAGCTTGAACTGCATCTG

SerAsnThrAsnLeuThrGluThrMetAsnThrThrAsnGlnGlnLeuGluLeuHisLeu

1441 GGAGGCGAGAGCTTTTGGGTGTCTATGATTTCTTATAATTCTCTTGGGAAGTCTCCAGTG

GlyGlyGluSerPheTrpValSerMetIleSerTyrAsnSerLeuGlyLysSerProVal

1501 GCCACCCTGAGGATTCCAGCTATTCAAGAAAAATCATTTCAGTGCATTGAGGTCATGCAG

AlaThrLeuArgIleProAlaIleGlnGluLysSerPheGlnCysIleGluValMetGln

1561 GCCTGCGTTGCTGAGGACCAGCTAGTGGTGAAGTGGCAAAGCTCTGCTCTAGACGTGAAC

AlaCysValAlaGluAspGlnLeuValValLysTrpGlnSerSerAlaLeuAspValAsn

1621 ACTTGGATGATTGAATGGTTTCCGGATGTGGACTCAGAGCCCACCACCCTTTCCTGGGAA

ThrTrpMetIleGluTrpPheProAspValAspSerGluProThrThrLeuSerTrpGlu

1681 TCTGTGTCTCAGGCCACGAACTGGACGATCCAGCAAGATAAATTAAAACCTTTCTGGTGC

SerValSerGlnAlaThrAsnTrpThrIleGlnGlnAspLysLeuLysProPheTrpCys

1741 TATAACATCTCTGTGTATCCAATGTTGCATGACAAAGTTGGCGAGCCATATTCCATCCAG

TyrAsnIleSerValTyrProMetLeuHisAspLysValGlyGluProTyrSerIleGln

1801 GCTTATGCCAAAGAAGGCGTTCCATCAGAAGGTCCTGAGACCAAGGTGGAGAACATTGGC

AlaTyrAlaLysGluGlyValProSerGluGlyProGluThrLysValGluAsnIleGly

1861 GTGAAGACGGTCACGATCACATGGAAAGAGATTCCCAAGAGTGAGAGAAAGGGTATCATC

ValLysThrValThrIleThrTrpLysGluIleProLysSerGluArgLysGlyIleIle

1921 TGCAACTACACCATCTTTTACCAAGCTGAAGGTGGAAAAGGATTCTCCAAGACAGTCAAT

CysAsnTyrThrIlePheTyrGlnAlaGluGlyGlyLysGlyPheSerLysThrValAsn

1981 TCCAGCATCTTGCAGTACGGCCTGGAGTCCCTGAAACGAAAGACCTCTTACATTGTTCAG

SerSerIleLeuGlnTyrGlyLeuGluSerLeuLysArgLysThrSerTyrIleValGln

2041 GTCATGGCCAACACCAGTGCTGGGGGAACCAACGGGACCAGCATAAATTTCAAGACATTG

ValMetAlaAsnThrSerAlaGlyGlyThrAsnGlyThrSerIleAsnPheLysThrLeu

2101 TCATTCAGTGTCTTTGAGATTATCCTCATAACTTCTCTGATTGGTGGAGGCCTTCTTATT

SerPheSerValPheGluIleIleLeuIleThrSerLeuIleGlyGlyGlyLeuLeuIle

Figure 5

```
2161  CTCATTATCCTGACAGTGGCATATGGTCTCAAAAAACCCAACAAATTGACTCATCTGTGT
      LeuIleIleLeuThrValAlaTyrGlyLeuLysLysProAsnLysLeuThrHisLeuCys
2221  TGGCCCACCGTTCCCAACCCTGCTGAAAGTAGTATAGCCACATGGCATGGAGATGATTTC
      TrpProThrValProAsnProAlaGluSerSerIleAlaThrTrpHisGlyAspAspPhe
2281  AAGGATAAGCTAAACCTGAAGGAGTCTGATGACTCTGTGAACACAGAAGACAGGATCTTA
      LysAspLysLeuAsnLeuLysGluSerAspAspSerValAsnThrGluAspArgIleLeu
2341  AAACCATGTTCCACCCCCAGTGACAAGTTGGTGATTGACAAGTTGGTGGTGAACTTTGGG
      LysProCysSerThrProSerAspLysLeuValIleAspLysLeuValValAsnPheGly
2401  AATGTTCTGCAAGAAATTTTCACAGATGAAGCCAGAACGGGTCAGGAAAAACAATTTAGG
      AsnValLeuGlnGluIlePheThrAspGluAlaArgThrGlyGlnGluLysGlnPheArg
2461  AGGGGAAAAGAATGGGACTAGAATTCTGTCTTCCTGCCCAACTTCAATATAAGTGTGGAC
      ArgGlyLysGluTrpAsp*** (SEQ ID NO:2)
2521  TAAAATGCGAGAAAGGTGTCCTGTGGTCTATGCAAATTAGAAAGGACATGCAGAGTTTTC
2581  CAACTAGGAAGACTGAATCTGTGGCCCCAAGAGAACCATCTCCGAAGACTGGGTATGTGG
2641  TCTTTTCCACACATGGACCACCTACGGATGCAATCTGTAATGCATGTGCATGAGAAGTCT
2701  GTTATTAAGTAGAGTGTGAAAACATGGTTATGGTAATAGGAACAGCTTTTAAAATGCTTT
2761  TGTATTTGGGCCTTTCACACAAAAAAGCCATAATACCATTTTCATGTAATGCTATACTTC
2821  TATACTATTTTCATGTAATACTATACTTCTATACTATTTTCATGTAATACTATACTTCTA
2881  TACTATTTTCATGTAATACTATACTTCTATATTAAAGTTTTACCCACTCCAAAAAAAGAA
2941  AAAAAAAAAAAAAAAAAAAAAAAAAAAAA (SEQ ID NO:1)
```

Figure 6

(SEQ ID NO:3)

```
   1 CGCTTATAAATGAATGTGTGCTTAGGAACACCAGACAGCACTCCAGCACTCTGCTTGGGG
  61 GGCATTCGAAACAGCAAAATCACTCATAAAAGGCAAAAAATTGCAAAAAAAATAGTAATA
 121 ACCAGCATGGTACTAAATAGACCATGAAAAGACATGTGTGTGCAGTATGAAAATTGAGAC
 181 AGGAAGGCAGAGTGTCAGCTTGTTCCACCTCAGCTGGGAATGTGCATCAGGCAACTCAAG
 241 TTTTTCACCACGGCATGTGTCTGTGAATGTCCGCAAAACATTTTAACAATAATGCAATCC
 301 ATTTCCCAGCATAAGTGGGTAAGTGCCACTTTGACTTGGGCTGGGCTTAAAAGCACAAGA
 361 AAAGCTCGCAGACAATCAGAGTGGAAACACTCCCACATCTTAGTGTGGATAAATTAAAGT
 421 CCAGATTGTTCTTCCTGTCCTGACTTGTGCTGTGGGAGGTGGAGTTGCCTTTGATGCAAA
 481 TCCTTTGAGCCAGCAGAACATCTGTGGAACATCCCCTGATACATGAAGCTCTCTCCCCAG
```

(SEQ ID NO:4) MetLysLeuSerProGln

```
 541 CCTTCATGTGTTAACCTGGGGATGATGTGGACCTGGGCACTGTGGATGCTCCCCTCACTC
     ProSerCysValAsnLeuGlyMetMetTrpThrTrpAlaLeuTrpMetLeuProSerLeu
 601 TGCAAATTCAGCCTGGCAGCTCTGCCAGCTAAGCCTGAGAACATTTCCTGTGTCTACTAC
     CysLysPheSerLeuAlaAlaLeuProAlaLysProGluAsnIleSerCysValTyrTyr
 661 TATAGGAAAAATTTAACCTGCACTTGGAGTCCAGGAAAGGAAACCAGTTATACCCAGTAC
     TyrArgLysAsnLeuThrCysThrTrpSerProGlyLysGluThrSerTyrThrGlnTyr
 721 ACAGTTAAGAGAACTTACGCTTTCGGAGAAAAACATGATAATTGTACAACCAATAGTTCT
     ThrValLysArgThrTyrAlaPheGlyGluLysHisAspAsnCysThrThrAsnSerSer
 781 ACAAGTGAAAATCGTGCTTCGTGCTCTTTTTTCCTTCCAAGAATAACGATCCCAGATAAT
     ThrSerGluAsnArgAlaSerCysSerPhePheLeuProArgIleThrIleProAspAsn
 841 TATACCATTGAGGTGGAAGCTGAAAATGGAGATGGTGTAATTAAATCTCATATGACATAC
     TyrThrIleGluValGluAlaGluAsnGlyAspGlyValIleLysSerHisMetThrTyr
 901 TGGAGATTAGAGAACATAGCGAAAACTGAACCACCTAAGATTTTCCGTGTGAAACCAGTT
     TrpArgLeuGluAsnIleAlaLysThrGluProProLysIlePheArgValLysProVal
 961 TTGGGCATCAAACGAATGATTCAAATTGAATGGATAAAGCCTGAGTTGGCGCCTGTTTCA
     LeuGlyIleLysArgMetIleGlnIleGluTrpIleLysProGluLeuAlaProValSer
1021 TCTGATTTAAAATACACACTTCGATTCAGGACAGTCAACAGTACCAGCTGGATGGAAGTC
     SerAspLeuLysTyrThrLeuArgPheArgThrValAsnSerThrSerTrpMetGluVal
1081 AACTTCGCTAAGAACCGTAAGGATAAAAACCAAACGTACAACCTCACGGGGCTGCAGCCT
     AsnPheAlaLysAsnArgLysAspLysAsnGlnThrTyrAsnLeuThrGlyLeuGlnPro
1141 TTTACAGAATATGTCATAGCTCTGCGATGTGCGGTCAAGGAGTCAAAGTTCTGGAGTGAC
     PheThrGluTyrValIleAlaLeuArgCysAlaValLysGluSerLysPheTrpSerAsp
```

Figure 7

```
1201  TGGAGCCAAGAAAAAATGGGAATGACTGAGGAAGAAGGCAAGCTACTCCCTGCGATTCCC
      TrpSerGlnGluLysMetGlyMetThrGluGluGluGlyLysLeuLeuProAlaIlePro
1261  GTCCTGTCTACTCTGGTGTAGGGCTGCTTTGGGCTAGACTTGGTGGGGTTTGTCACCACC
      ValLeuSerThrLeuVal***  (SEQ ID NO:4)
1321  TGGTTGGGAATCATGGAATCTCATGACCCCAGGGGCCCCCTGTACCATCGAGAGTGAGCC
1381  TGCACAACTTTGTGCCCCAAAGGCAAAGGATCACATTTTAATACTCATGAGGTTCTTATA
1441  CTATACATGAAAGGGTATCATATCATTTGTTTTGTTTTGTTTTGTTTTTGAGATGGAGTC
1501  TTACTCTGTCACCCAGGATGGAGTGCAGTGATGTGATCTCGGCTCACTGCCACCACCACC
1561  TCCCGAGTTCAAGCAATTCTTGTGCCTCAGCCTCCCAAGTAGCTGGGATTACAGGGGCCC
1621  ACGACCATGCCCGGTTGATTTTTGTATTTTTAGTAGAGAAGGGATATCACCATGTTGGCT
1681  AGGCTAGTCTTGAACTCCTGACCTCAGGTAATCTGCCCACCTTGACCTCCCAAAGTGTTG
1741  GGATTACAGGCGTGAGCCACTGTGCCCCGCCAGTATCATATCATCTGAAGGTATCCTGTG
1801  ATAAATTAAAGATACATATTGTGAATCCTGGAGCTACTACTCAAAAAATAAATAAAGGTG
1861  TAACTAATACAATTTAAAAAATCACATTTTTAATGACAGTGAGGAAAGGAAAGAGGCATG
1921  GATTGCAGGTTGATGGAGTGCTTACTAAGTGTCAGTATGGTCATTAAGAGCAACGCTTCC
1981  AGTCAGTGGCCTTGGCTTAAATCCCAAGCCAGGTGTCTTTGGGCAAGATACCTAAACTCT
2041  CAGTTCATTCTCAGCAGTTTCCTCGCATTTATTCCCCTTTTCTATATTGAAATAGAATAT
2101  GTAAGTTGAGTTTATAGTAGTACCTATTTTTTAGTATTATTTTAAAGATTAAATGAAATA
2161  ATGTGTTTAGCCCATAGTAGATATTCACTAACTGCTAGACTTCCTATTCTTATTATTTAT
2221  CCTCCTACTATTATTTTTAATCCTCCTTAAAGCACTATAAAATATGTAGAGTCACTCCCA
2281  TTTTGGAAATGAGGAAACTGAGTTTCAGAGATGCTAATAAACAGCTCAGGGTCACTCAGC
2341  ATGTGTTACTTTTCTCAAGAGCCTTGCCCAGAGTCTGACCCTCAGTGGACGATCAATAAA
2401  TGTGTGATGAATGGAAAAAAAAAAAAAAAAAAAAAAAAA  (SEQ ID NO:3)
```

Figure 13

(SEQ ID NO:16)

```
   1 CCCCTGATACATGAAGCTCTCTCCCCAGCCTTCATGTGTTAACCTGGGGATGATGTGGAC
(SEQ ID NO:17)  MetLysLeuSerProGlnProSerCysValAsnLeuGlyMetMetTrpThr
  61 CTGGGCACTGTGGATGCTCCCCTCACTCTGCAAATTCAGCCTGGCAGCTCTGCCAGCTAA
     TrpAlaLeuTrpMetLeuProSerLeuCysLysPheSerLeuAlaAlaLeuProAlaLys
 121 GCCTGAGAACATTTCCTGTGTCTACTACTATAGGAAAAATTTAACCTGCACTTGGAGTCC
     ProGluAsnIleSerCysValTyrTyrTyrArgLysAsnLeuThrCysThrTrpSerPro
 181 AGGAAAGGAAACCAGTTATACCCAGTACACAGTTAAGAGAACTTACGCTTTTGGAGAAAA
     GlyLysGluThrSerTyrThrGlnTyrThrValLysArgThrTyrAlaPheGlyGluLys
 241 ACATGATAATTGTACAACCAATAGTTCTACAAGTGAAAATCGTGCTTCGTGCTCTTTTTT
     HisAspAsnCysThrThrAsnSerSerThrSerGluAsnArgAlaSerCysSerPhePhe
 301 CCTTCCAAGAATAACGATCCCAGATAATTATACCATTGAGGTGGAAGCTGAAAATGGAGA
     LeuProArgIleThrIleProAspAsnTyrThrIleGluValGluAlaGluAsnGlyAsp
 361 TGGTGTAATTAAATCTCATATGACATACTGGAGATTAGAGAACATAGCGAAAACTGAACC
     GlyValIleLysSerHisMetThrTyrTrpArgLeuGluAsnIleAlaLysThrGluPro
 421 ACCTAAGATTTTCCGTGTGAAACCAGTTTTGGGCATCAAACGAATGATTCAAATTGAATG
     ProLysIlePheArgValLysProValLeuGlyIleLysArgMetIleGlnIleGluTrp
 481 GATAAAGCCTGAGTTGGCGCCTGTTTCATCTGATTTAAAATACACACTTCGATTCAGGAC
     IleLysProGluLeuAlaProValSerSerAspLeuLysTyrThrLeuArgPheArgThr
 541 AGTCAACAGTACCAGCTGGATGGAAGTCAACTTCGCTAAGAACCGTAAGGATAAAAACCA
     ValAsnSerThrSerTrpMetGluValAsnPheAlaLysAsnArgLysAspLysAsnGln
 601 AACGTACAACCTCACGGGGCTGCAGCCTTTTACAGAATATGTCATAGCTCTGCGATGTGC
     ThrTyrAsnLeuThrGlyLeuGlnProPheThrGluTyrValIleAlaLeuArgCysAla
 661 GGTCAAGGAGTCAAAGTTCTGGAGTGACTGGAGCCAAGAAAAAATGGGAATGACTGAGGA
     ValLysGluSerLysPheTrpSerAspTrpSerGlnGluLysMetGlyMetThrGluGlu
 721 AGAAGCTCCATGTGGCCTGGAACTGTGGAGAGTCCTGAAACCAGCTGAGGCGGATGGAAG
     GluAlaProCysGlyLeuGluLeuTrpArgValLeuLysProAlaGluAlaAspGlyArg
 781 AAGGCCAGTGCGGTTGTTATGGAAGAAGGCAAGAGGAGCCCCAGTCCTAGAGAAAACACT
     ArgProValArgLeuLeuTrpLysLysAlaArgGlyAlaProValLeuGluLysThrLeu
 841 TGGCTACAACATATGGTACTATCCAGAAAGCAACACTAACCTCACAGAAACAATGAACAC
     GlyTyrAsnIleTrpTyrTyrProGluSerAsnThrAsnLeuThrGluThrMetAsnThr
 901 TACTAACCAGCAGCTTGAACTGCATCTGGGAGGCGAGAGCTTTTGGGTGTCTATGATTTC
     ThrAsnGlnGlnLeuGluLeuHisLeuGlyGlyGluSerPheTrpValSerMetIleSer
 961 TTATAATTCTCTTGGGAAGTCTCCAGTGGCCACCCTGAGGATTCCAGCTATTCAAGAAAA
     TyrAsnSerLeuGlyLysSerProValAlaThrLeuArgIleProAlaIleGlnGluLys
1021 ATCATTTCAGTGCATTGAGGTCATGCAGGCCTGCGTTGCTGAGGACCAGCTAGTGGTGAA
```

Figure 14

```
      SerPheGlnCysIleGluValMetGlnAlaCysValAlaGluAspGlnLeuValValLys
1081  GTGGCAAAGCTCTGCTCTAGACGTGAACACTTGGATGATTGAATGGTTTCCGGATGTGGA
      TrpGlnSerSerAlaLeuAspValAsnThrTrpMetIleGluTrpPheProAspValAsp
1141  CTCAGAGCCCACCACCCTTTCCTGGGAATCTGTGTCTCAGGCCACGAACTGGACGATCCA
      SerGluProThrThrLeuSerTrpGluSerValSerGlnAlaThrAsnTrpThrIleGln
1201  GCAAGATAAATTAAAACCTTTCTGGTGCTATAACATCTCTGTGTATCCAATGTTGCATGA
      GlnAspLysLeuLysProPheTrpCysTyrAsnIleSerValTyrProMetLeuHisAsp
1261  CAAAGTTGGCGAGCCATATTCCATCCAGGCTTATGCCAAAGAAGGCGTTCCATCAGAAGG
      LysValGlyGluProTyrSerIleGlnAlaTyrAlaLysGluGlyValProSerGluGly
1321  TCCTGAGACCAAGGTGGAGAACATTGGCGTGAAGACGGTCACGATCACATGGAAAGAGAT
      ProGluThrLysValGluAsnIleGlyValLysThrValThrIleThrTrpLysGluIle
1381  TCCCAAGAGTGAGAGAAAGGGTATCATCTGCAACTACACCATCTTTTACCAAGCTGAAGG
      ProLysSerGluArgLysGlyIleIleCysAsnTyrThrIlePheTyrGlnAlaGluGly
1441  TGGAAAAGGATTCTCCAAGACAGTCAATTCCAGCATCTTGCAGTACGGCCTGGAGTCCCT
      GlyLysGlyPheSerLysThrValAsnSerSerIleLeuGlnTyrGlyLeuGluSerLeu
1501  GAAACGAAAGACCTCTTACATTGTTCAGGTCATGGCCAGCACCAGTGCTGGGGGAACCAA
      LysArgLysThrSerTyrIleValGlnValMetAlaSerThrSerAlaGlyGlyThrAsn
1561  CGGGACCAGCATAAATTTCAAGACATTGTCATTCAGTGTCTTTGAGATTATCCTCATAAC
      GlyThrSerIleAsnPheLysThrLeuSerPheSerValPheGluIleIleLeuIleThr
1621  TTCTCTGATTGGTGGAGGCCTTCTTATTCTCATTATCCTGACAGTGGCATATGGTCTCAA
      SerLeuIleGlyGlyGlyLeuLeuIleLeuIleIleLeuThrValAlaTyrGlyLeuLys
1681  AAAACCCAACAAATTGACTCATCTGTGTTGGCCCACCGTTCCCAACCCTGCTGAAAGTAG
      LysProAsnLysLeuThrHisLeuCysTrpProThrValProAsnProAlaGluSerSer
1741  TATAGCCACATGGCATGGAGATGATTTCAAGGATAAGCTAAACCTGAAGGAGTCTGATGA
      IleAlaThrTrpHisGlyAspAspPheLysAspLysLeuAsnLeuLysGluSerAspAsp
1801  CTCTGTGAACACAGAAGACAGGATCTTAAAACCATGTTCCACCCCCAGTGACAAGTTGGT
      SerValAsnThrGluAspArgIleLeuLysProCysSerThrProSerAspLysLeuVal
1861  GATTGACAAGTTGGTGGTGAACTTTGGGAATGTTCTGCAAGAAATTTTCACAGATGAAGC
      IleAspLysLeuValValAsnPheGlyAsnValLeuGlnGluIlePheThrAspGluAla
1921  CAGAACGGGTCAGGAAAACAATTTAGGAGGGGAAAAGAATGGGACTAGAATTCTGTCTTC
      ArgThrGlyGlnGluAsnAsnLeuGlyGlyGluLysAsnGlyThrArgIleLeuSerSer
1981  CTGCCCAACTTCAATATAAGTGTGGACTAAAATGCGAGAAAGGTGTCCTGTGGTCTATGC
      CysProThrSerIle*** (SEQ ID NO:17)
2041  AAATTAGAAAGGACATGCAGAGTTTTCCAACTAGGAAGACTGAATCTGTGGCCCCAAGAG

2101  AACCATCTCCGAAGACTGG (SEQ ID NO:16)
```